4.7 Review

Review article: spontaneous bacterial peritonitis - bacteriology, diagnosis, treatment, risk factors and prevention

期刊

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 41, 期 11, 页码 1116-1131

出版社

WILEY
DOI: 10.1111/apt.13172

关键词

-

向作者/读者索取更多资源

BackgroundSpontaneous bacterial peritonitis (SBP) is a severe and often fatal infection in patients with cirrhosis and ascites. AimTo review the known and changing bacteriology, risk factors, ascitic fluid interpretation, steps in performing paracentesis, treatment, prophylaxis and evolving perspectives related to SBP. MethodsInformation was obtained from reviewing medical literature accessible on PubMed Central. The search term spontaneous bacterial peritonitis' was cross-referenced with bacteria', risk factors', ascites', paracentesis', ascitic fluid analysis', diagnosis', treatment', antibiotics', prophylaxis', liver transplantation' and nutrition'. ResultsGram-positive cocci (GPC) such as Staphylococcus, Enterococcus as well as multi-resistant bacteria have become common pathogens and have changed the conventional approach to treatment of SBP. Health care-associated and nosocomial SBP infections should prompt greater vigilance and consideration for alternative antibiotic coverage. Acid suppressive and beta-adrenergic antagonist therapies are strongly associated with SBP in at-risk individuals. ConclusionsThird-generation, broad-spectrum cephalosporins remain a good initial choice for SBP treatment. Levofloxacin is an acceptable alternative for patients not receiving long-term flouroquinolone prophylaxis or for those with a penicillin allergy. For uncomplicated SBP, early oral switch therapy is reasonable. Alternative antibiotics such as pipercillin-tazobactam should be considered for patients with nosocomial SBP or for patients who fail to improve on traditional antibiotic regimens. Selective albumin supplementation remains an important adjunct in SBP treatment. Withholding acid suppressive medication deserves strong consideration, and discontinuing beta-adrenergic antagonist therapy in patients with end-stage liver disease and resistant ascites is standard care. Liver transplant evaluation should be undertaken for patients who develop SBP barring contraindications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据